DUSP22 and schizophrenia: In the case-control blood samples, five of 15 schizophrenia patients were current smokers in contrast to three of 49 smokers in the healthy controls (χ2 test, p = 0.02), DUSP22 promoter methylation was not associated with schizophrenia status (B = −0.79, p = 0.223).